Jessie J. Wang, Binchen Mao, Sheng Guo, Davy X. Ouyang, Henry Q. Li
Predictive biomarkers are crucial for selecting the most effective treatment for cancer patients. Large panels of clinically-relevant patient-derived xenograft (PDX) models are used preclinically to discover or validate predictive biomarkers, generating hypotheses for clinical testing.
Colorectal cancer PDX have been used to identify potential biomarkers with a predictive value for FOLFOX treatment. FOLFOX is a common first-line chemotherapy for adjuvant and/or neoadjuvant colorectal cancer treatment, but mutations of oncogenes such as KRAS may limit patient response.
This poster correlates colorectal cancer PDX response to FOLFOX treatment with model genomic background, to identify genes with significant correlation to response or resistance.